Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation

This publication has 46 references indexed in Scilit:

• Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
  Clinical Cancer Research, 2008
• IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity
  Blood, 2007
• Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes
  Clinical and Experimental Immunology, 2007
• Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
  Blood, 2005
• Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity
  Endocrine-Related Cancer, 2005
• CD4⁺CD25⁺ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
  European Journal of Immunology, 2004
• Enhanced Tumor Protection by Granulocyte-Macrophage Colony-Stimulating Factor Expression at the Site of an Allogeneic Vaccine
  Human Gene Therapy, 1998
• Enhancing the Effect of THERATOPE STn-KLH Cancer Vaccine in Patients with Metastatic Breast Cancer by Pretreatment with Low-Dose Intravenous Cyclophosphamide
  Journal of Immunotherapy, 1996
• Enhanced Immune Priming with Spatial Distribution of Paracrine Cytokine Vaccines
  Journal of Immunotherapy, 1996
• On some statistical methods for analysis of combination drug studies^∗
  Communications in Statistics - Theory and Methods, 1994